2018-2023 Global Neuromyelitis Optica Drug Consumption Market Report

October 2018 | 162 pages | ID: 2F7F19E3118EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Neuromyelitis Optica Drug market for 2018-2023.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.
Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.
Over the next five years, LPI(LP Information) projects that Neuromyelitis Optica Drug will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuromyelitis Optica Drug market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Glucocorticoids
• Immunoglobulin

Segmentation by application:

• Acute attack
• Remission prophylactic treatment

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Pfizer
• FRESENIUS
• TEVA
• SANDOZ
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL
• Grifols
• Octapharma
• CBOP

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Neuromyelitis Optica Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Neuromyelitis Optica Drug market by identifying its various subsegments.
• Focuses on the key global Neuromyelitis Optica Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Neuromyelitis Optica Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Neuromyelitis Optica Drug submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Neuromyelitis Optica Drug Consumption 2013-2023
  2.1.2 Neuromyelitis Optica Drug Consumption CAGR by Region
2.2 Neuromyelitis Optica Drug Segment by Type
  2.2.1 Glucocorticoids
  2.2.2 Immunoglobulin
2.3 Neuromyelitis Optica Drug Consumption by Type
  2.3.1 Global Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
  2.3.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Neuromyelitis Optica Drug Sale Price by Type (2013-2018)
2.4 Neuromyelitis Optica Drug Segment by Application
  2.4.1 Acute attack
  2.4.2 Remission prophylactic treatment
2.5 Neuromyelitis Optica Drug Consumption by Application
  2.5.1 Global Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
  2.5.2 Global Neuromyelitis Optica Drug Value and Market Share by Application (2013-2018)
  2.5.3 Global Neuromyelitis Optica Drug Sale Price by Application (2013-2018)

3 GLOBAL NEUROMYELITIS OPTICA DRUG BY PLAYERS

3.1 Global Neuromyelitis Optica Drug Sales Market Share by Players
  3.1.1 Global Neuromyelitis Optica Drug Sales by Players (2016-2018)
  3.1.2 Global Neuromyelitis Optica Drug Sales Market Share by Players (2016-2018)
3.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players
  3.2.1 Global Neuromyelitis Optica Drug Revenue by Players (2016-2018)
  3.2.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2016-2018)
3.3 Global Neuromyelitis Optica Drug Sale Price by Players
3.4 Global Neuromyelitis Optica Drug Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Neuromyelitis Optica Drug Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Neuromyelitis Optica Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 NEUROMYELITIS OPTICA DRUG BY REGIONS

4.1 Neuromyelitis Optica Drug by Regions
  4.1.1 Global Neuromyelitis Optica Drug Consumption by Regions
  4.1.2 Global Neuromyelitis Optica Drug Value by Regions
4.2 Americas Neuromyelitis Optica Drug Consumption Growth
4.3 APAC Neuromyelitis Optica Drug Consumption Growth
4.4 Europe Neuromyelitis Optica Drug Consumption Growth
4.5 Middle East & Africa Neuromyelitis Optica Drug Consumption Growth

5 AMERICAS

5.1 Americas Neuromyelitis Optica Drug Consumption by Countries
  5.1.1 Americas Neuromyelitis Optica Drug Consumption by Countries (2013-2018)
  5.1.2 Americas Neuromyelitis Optica Drug Value by Countries (2013-2018)
5.2 Americas Neuromyelitis Optica Drug Consumption by Type
5.3 Americas Neuromyelitis Optica Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Neuromyelitis Optica Drug Consumption by Countries
  6.1.1 APAC Neuromyelitis Optica Drug Consumption by Countries (2013-2018)
  6.1.2 APAC Neuromyelitis Optica Drug Value by Countries (2013-2018)
6.2 APAC Neuromyelitis Optica Drug Consumption by Type
6.3 APAC Neuromyelitis Optica Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Neuromyelitis Optica Drug by Countries
  7.1.1 Europe Neuromyelitis Optica Drug Consumption by Countries (2013-2018)
  7.1.2 Europe Neuromyelitis Optica Drug Value by Countries (2013-2018)
7.2 Europe Neuromyelitis Optica Drug Consumption by Type
7.3 Europe Neuromyelitis Optica Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neuromyelitis Optica Drug by Countries
  8.1.1 Middle East & Africa Neuromyelitis Optica Drug Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Neuromyelitis Optica Drug Value by Countries (2013-2018)
8.2 Middle East & Africa Neuromyelitis Optica Drug Consumption by Type
8.3 Middle East & Africa Neuromyelitis Optica Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Neuromyelitis Optica Drug Distributors
10.3 Neuromyelitis Optica Drug Customer

11 GLOBAL NEUROMYELITIS OPTICA DRUG MARKET FORECAST

11.1 Global Neuromyelitis Optica Drug Consumption Forecast (2018-2023)
11.2 Global Neuromyelitis Optica Drug Forecast by Regions
  11.2.1 Global Neuromyelitis Optica Drug Forecast by Regions (2018-2023)
  11.2.2 Global Neuromyelitis Optica Drug Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Neuromyelitis Optica Drug Forecast by Type
11.8 Global Neuromyelitis Optica Drug Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Pfizer
  12.1.1 Company Details
  12.1.2 Neuromyelitis Optica Drug Product Offered
  12.1.3 Pfizer Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Pfizer News
12.2 FRESENIUS
  12.2.1 Company Details
  12.2.2 Neuromyelitis Optica Drug Product Offered
  12.2.3 FRESENIUS Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 FRESENIUS News
12.3 TEVA
  12.3.1 Company Details
  12.3.2 Neuromyelitis Optica Drug Product Offered
  12.3.3 TEVA Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 TEVA News
12.4 SANDOZ
  12.4.1 Company Details
  12.4.2 Neuromyelitis Optica Drug Product Offered
  12.4.3 SANDOZ Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 SANDOZ News
12.5 Intas
  12.5.1 Company Details
  12.5.2 Neuromyelitis Optica Drug Product Offered
  12.5.3 Intas Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Intas News
12.6 Gyjtrs
  12.6.1 Company Details
  12.6.2 Neuromyelitis Optica Drug Product Offered
  12.6.3 Gyjtrs Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Gyjtrs News
12.7 NANG KUANG
  12.7.1 Company Details
  12.7.2 Neuromyelitis Optica Drug Product Offered
  12.7.3 NANG KUANG Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 NANG KUANG News
12.8 Tianjin Kingyork
  12.8.1 Company Details
  12.8.2 Neuromyelitis Optica Drug Product Offered
  12.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Tianjin Kingyork News
12.9 Baxter
  12.9.1 Company Details
  12.9.2 Neuromyelitis Optica Drug Product Offered
  12.9.3 Baxter Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Baxter News
12.10 CSL
  12.10.1 Company Details
  12.10.2 Neuromyelitis Optica Drug Product Offered
  12.10.3 CSL Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 CSL News
12.11 Grifols
12.12 Octapharma
12.13 CBOP

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Neuromyelitis Optica Drug
Table Product Specifications of Neuromyelitis Optica Drug
Figure Neuromyelitis Optica Drug Report Years Considered
Figure Market Research Methodology
Figure Global Neuromyelitis Optica Drug Consumption Growth Rate 2013-2023 (K Units)
Figure Global Neuromyelitis Optica Drug Value Growth Rate 2013-2023 ($ Millions)
Table Neuromyelitis Optica Drug Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Glucocorticoids
Table Major Players of Glucocorticoids
Figure Product Picture of Immunoglobulin
Table Major Players of Immunoglobulin
Table Global Consumption Sales by Type (2013-2018)
Table Global Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Figure Global Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Table Global Neuromyelitis Optica Drug Revenue by Type (2013-2018) ($ million)
Table Global Neuromyelitis Optica Drug Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Neuromyelitis Optica Drug Value Market Share by Type (2013-2018)
Table Global Neuromyelitis Optica Drug Sale Price by Type (2013-2018)
Figure Neuromyelitis Optica Drug Consumed in Acute attack
Figure Global Neuromyelitis Optica Drug Market: Acute attack (2013-2018) (K Units)
Figure Global Neuromyelitis Optica Drug Market: Acute attack (2013-2018) ($ Millions)
Figure Global Acute attack YoY Growth ($ Millions)
Figure Neuromyelitis Optica Drug Consumed in Remission prophylactic treatment
Figure Global Neuromyelitis Optica Drug Market: Remission prophylactic treatment (2013-2018) (K Units)
Figure Global Neuromyelitis Optica Drug Market: Remission prophylactic treatment (2013-2018) ($ Millions)
Figure Global Remission prophylactic treatment YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Figure Global Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Table Global Neuromyelitis Optica Drug Value by Application (2013-2018)
Table Global Neuromyelitis Optica Drug Value Market Share by Application (2013-2018)
Figure Global Neuromyelitis Optica Drug Value Market Share by Application (2013-2018)
Table Global Neuromyelitis Optica Drug Sale Price by Application (2013-2018)
Table Global Neuromyelitis Optica Drug Sales by Players (2016-2018) (K Units)
Table Global Neuromyelitis Optica Drug Sales Market Share by Players (2016-2018)
Figure Global Neuromyelitis Optica Drug Sales Market Share by Players in 2016
Figure Global Neuromyelitis Optica Drug Sales Market Share by Players in 2017
Table Global Neuromyelitis Optica Drug Revenue by Players (2016-2018) ($ Millions)
Table Global Neuromyelitis Optica Drug Revenue Market Share by Players (2016-2018)
Figure Global Neuromyelitis Optica Drug Revenue Market Share by Players in 2016
Figure Global Neuromyelitis Optica Drug Revenue Market Share by Players in 2017
Table Global Neuromyelitis Optica Drug Sale Price by Players (2016-2018)
Figure Global Neuromyelitis Optica Drug Sale Price by Players in 2017
Table Global Neuromyelitis Optica Drug Manufacturing Base Distribution and Sales Area by Players
Table Players Neuromyelitis Optica Drug Products Offered
Table Neuromyelitis Optica Drug Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Neuromyelitis Optica Drug Consumption by Regions 2013-2018 (K Units)
Table Global Neuromyelitis Optica Drug Consumption Market Share by Regions 2013-2018
Figure Global Neuromyelitis Optica Drug Consumption Market Share by Regions 2013-2018
Table Global Neuromyelitis Optica Drug Value by Regions 2013-2018 ($ Millions)
Table Global Neuromyelitis Optica Drug Value Market Share by Regions 2013-2018
Figure Global Neuromyelitis Optica Drug Value Market Share by Regions 2013-2018
Figure Americas Neuromyelitis Optica Drug Consumption 2013-2018 (K Units)
Figure Americas Neuromyelitis Optica Drug Value 2013-2018 ($ Millions)
Figure APAC Neuromyelitis Optica Drug Consumption 2013-2018 (K Units)
Figure APAC Neuromyelitis Optica Drug Value 2013-2018 ($ Millions)
Figure Europe Neuromyelitis Optica Drug Consumption 2013-2018 (K Units)
Figure Europe Neuromyelitis Optica Drug Value 2013-2018 ($ Millions)
Figure Middle East & Africa Neuromyelitis Optica Drug Consumption 2013-2018 (K Units)
Figure Middle East & Africa Neuromyelitis Optica Drug Value 2013-2018 ($ Millions)
Table Americas Neuromyelitis Optica Drug Consumption by Countries (2013-2018) (K Units)
Table Americas Neuromyelitis Optica Drug Consumption Market Share by Countries (2013-2018)
Figure Americas Neuromyelitis Optica Drug Consumption Market Share by Countries in 2017
Table Americas Neuromyelitis Optica Drug Value by Countries (2013-2018) ($ Millions)
Table Americas Neuromyelitis Optica Drug Value Market Share by Countries (2013-2018)
Figure Americas Neuromyelitis Optica Drug Value Market Share by Countries in 2017
Table Americas Neuromyelitis Optica Drug Consumption by Type (2013-2018) (K Units)
Table Americas Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Figure Americas Neuromyelitis Optica Drug Consumption Market Share by Type in 2017
Table Americas Neuromyelitis Optica Drug Consumption by Application (2013-2018) (K Units)
Table Americas Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Figure Americas Neuromyelitis Optica Drug Consumption Market Share by Application in 2017
Figure United States Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure United States Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Canada Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Canada Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Mexico Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Mexico Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Table APAC Neuromyelitis Optica Drug Consumption by Countries (2013-2018) (K Units)
Table APAC Neuromyelitis Optica Drug Consumption Market Share by Countries (2013-2018)
Figure APAC Neuromyelitis Optica Drug Consumption Market Share by Countries in 2017
Table APAC Neuromyelitis Optica Drug Value by Countries (2013-2018) ($ Millions)
Table APAC Neuromyelitis Optica Drug Value Market Share by Countries (2013-2018)
Figure APAC Neuromyelitis Optica Drug Value Market Share by Countries in 2017
Table APAC Neuromyelitis Optica Drug Consumption by Type (2013-2018) (K Units)
Table APAC Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Figure APAC Neuromyelitis Optica Drug Consumption Market Share by Type in 2017
Table APAC Neuromyelitis Optica Drug Consumption by Application (2013-2018) (K Units)
Table APAC Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Figure APAC Neuromyelitis Optica Drug Consumption Market Share by Application in 2017
Figure China Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure China Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Japan Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Japan Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Korea Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Korea Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Southeast Asia Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure India Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure India Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Australia Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Australia Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Table Europe Neuromyelitis Optica Drug Consumption by Countries (2013-2018) (K Units)
Table Europe Neuromyelitis Optica Drug Consumption Market Share by Countries (2013-2018)
Figure Europe Neuromyelitis Optica Drug Consumption Market Share by Countries in 2017
Table Europe Neuromyelitis Optica Drug Value by Countries (2013-2018) ($ Millions)
Table Europe Neuromyelitis Optica Drug Value Market Share by Countries (2013-2018)
Figure Europe Neuromyelitis Optica Drug Value Market Share by Countries in 2017
Table Europe Neuromyelitis Optica Drug Consumption by Type (2013-2018) (K Units)
Table Europe Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Figure Europe Neuromyelitis Optica Drug Consumption Market Share by Type in 2017
Table Europe Neuromyelitis Optica Drug Consumption by Application (2013-2018) (K Units)
Table Europe Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Figure Europe Neuromyelitis Optica Drug Consumption Market Share by Application in 2017
Figure Germany Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Germany Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure France Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure France Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure UK Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure UK Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Italy Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Italy Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Russia Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Russia Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Spain Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Spain Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Neuromyelitis Optica Drug Consumption by Countries (2013-2018) (K Units)
Table Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Countries in 2017
Table Middle East & Africa Neuromyelitis Optica Drug Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Neuromyelitis Optica Drug Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Neuromyelitis Optica Drug Value Market Share by Countries in 2017
Table Middle East & Africa Neuromyelitis Optica Drug Consumption by Type (2013-2018) (K Units)
Table Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Type in 2017
Table Middle East & Africa Neuromyelitis Optica Drug Consumption by Application (2013-2018) (K Units)
Table Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Neuromyelitis Optica Drug Consumption Market Share by Application in 2017
Figure Egypt Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Egypt Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure South Africa Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure South Africa Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Israel Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Israel Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure Turkey Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure Turkey Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Neuromyelitis Optica Drug Consumption Growth 2013-2018 (K Units)
Figure GCC Countries Neuromyelitis Optica Drug Value Growth 2013-2018 ($ Millions)
Table Neuromyelitis Optica Drug Distributors List
Table Neuromyelitis Optica Drug Customer List
Figure Global Neuromyelitis Optica Drug Consumption Growth Rate Forecast (2018-2023) (K Units)
Figure Global Neuromyelitis Optica Drug Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Neuromyelitis Optica Drug Consumption Forecast by Countries (2018-2023) (K Units)
Table Global Neuromyelitis Optica Drug Consumption Market Forecast by Regions
Table Global Neuromyelitis Optica Drug Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Neuromyelitis Optica Drug Value Market Share Forecast by Regions
Figure Americas Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Americas Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure APAC Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure APAC Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Europe Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Europe Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Middle East & Africa Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Middle East & Africa Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure United States Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure United States Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Canada Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Canada Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Mexico Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Mexico Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Brazil Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Brazil Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure China Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure China Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Japan Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Japan Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Korea Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Korea Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Southeast Asia Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Southeast Asia Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure India Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure India Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Australia Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Australia Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Germany Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Germany Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure France Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure France Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure UK Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure UK Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Italy Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Italy Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Russia Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Russia Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Spain Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Spain Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Egypt Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Egypt Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure South Africa Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure South Africa Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Israel Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Israel Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure Turkey Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure Turkey Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Figure GCC Countries Neuromyelitis Optica Drug Consumption 2018-2023 (K Units)
Figure GCC Countries Neuromyelitis Optica Drug Value 2018-2023 ($ Millions)
Table Global Neuromyelitis Optica Drug Consumption Forecast by Type (2018-2023) (K Units)
Table Global Neuromyelitis Optica Drug Consumption Market Share Forecast by Type (2018-2023)
Table Global Neuromyelitis Optica Drug Value Forecast by Type (2018-2023) ($ Millions)
Table Global Neuromyelitis Optica Drug Value Market Share Forecast by Type (2018-2023)
Table Global Neuromyelitis Optica Drug Consumption Forecast by Application (2018-2023) (K Units)
Table Global Neuromyelitis Optica Drug Consumption Market Share Forecast by Application (2018-2023)
Table Global Neuromyelitis Optica Drug Value Forecast by Application (2018-2023) ($ Millions)
Table Global Neuromyelitis Optica Drug Value Market Share Forecast by Application (2018-2023)
Table Pfizer Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Neuromyelitis Optica Drug Market Share (2016-2018)
Table FRESENIUS Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table FRESENIUS Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure FRESENIUS Neuromyelitis Optica Drug Market Share (2016-2018)
Table TEVA Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table TEVA Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure TEVA Neuromyelitis Optica Drug Market Share (2016-2018)
Table SANDOZ Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table SANDOZ Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure SANDOZ Neuromyelitis Optica Drug Market Share (2016-2018)
Table Intas Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Intas Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Intas Neuromyelitis Optica Drug Market Share (2016-2018)
Table Gyjtrs Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Gyjtrs Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Gyjtrs Neuromyelitis Optica Drug Market Share (2016-2018)
Table NANG KUANG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table NANG KUANG Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure NANG KUANG Neuromyelitis Optica Drug Market Share (2016-2018)
Table Tianjin Kingyork Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Tianjin Kingyork Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Tianjin Kingyork Neuromyelitis Optica Drug Market Share (2016-2018)
Table Baxter Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Baxter Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Baxter Neuromyelitis Optica Drug Market Share (2016-2018)
Table CSL Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table CSL Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure CSL Neuromyelitis Optica Drug Market Share (2016-2018)
Table Grifols Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Octapharma Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table CBOP Basic Information, Manufacturing Base, Sales Area and Its Competitors